MapLight Therapeutics plans 36,979-share stock sale

MapLight Therapeutics, Inc. has a notice covering the proposed sale of 36979 shares of MapLight voting common stock through Morgan Stanley Smith Barney LLC, with an aggregate market value of 1401874.00 and an approximate sale date of 07/15/2026.

Rhea-AI Filing Summary

MapLight Therapeutics, Inc. has a notice covering the proposed sale of 36979 shares of MapLight voting common stock through Morgan Stanley Smith Barney LLC, with an aggregate market value of 1401874.00 and an approximate sale date of 07/15/2026. The shares are associated with a restricted stock unit settlement. The notice also lists prior April 2026 sales of MapLight voting common stock, including transactions for 3590, 51900 and 17935 shares on 04/15/2026, 04/27/2026 and 04/28/2026, respectively, with corresponding cash proceeds disclosed.

Key Figures

Shares to be sold: 36979 Aggregate market value of shares to be sold: 1401874.00 Shares outstanding: 42618165 +5 more

8 metrics

Shares to be sold 36979 MapLight voting common stock covered by the Form 144 notice

Aggregate market value of shares to be sold 1401874.00 Value of 36979 shares of MapLight voting common stock in planned sale

Shares outstanding 42618165 MapLight voting common stock shares outstanding as referenced in the notice

Shares sold on 04/15/2026 3590 MapLight voting common stock sold during past 3 months on 04/15/2026

Shares sold on 04/27/2026 51900 MapLight voting common stock sold during past 3 months on 04/27/2026

Proceeds on 04/27/2026 1543369.00 Gross proceeds from MapLight voting common stock sale on 04/27/2026

Shares sold on 04/28/2026 17935 MapLight voting common stock sold during past 3 months on 04/28/2026

Proceeds on 04/28/2026 544319.00 Gross proceeds from MapLight voting common stock sale on 04/28/2026

Key Terms

Securities To Be Sold, Restricted stock unit settlement, Securities Sold During The Past 3 Months, voting common stock

4 terms

Securities To Be Sold regulatory

"144: Securities To Be Sold MapLight voting common stock | 07/15/2026"

Restricted stock unit settlement financial

"07/15/2026 | Restricted stock unit settlement | MapLight Therapeutics, Inc."

Securities Sold During The Past 3 Months regulatory

"144: Securities Sold During The Past 3 Months Jonathan Gillis"

voting common stock market

"MapLight voting common stock | Morgan Stanley Smith Barney LLC"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What stock sale is covered in MapLight Therapeutics (MPLT) Form 144?

The notice covers a planned sale of 36979 shares of MapLight voting common stock through Morgan Stanley Smith Barney LLC, with an aggregate market value of 1401874.00 and an approximate sale date of 07/15/2026. The shares relate to a restricted stock unit settlement.

What prior MapLight Therapeutics (MPLT) stock sales are disclosed for the past 3 months?

The filing lists April 2026 sales of MapLight voting common stock, including 3590 shares on 04/15/2026, 51900 shares on 04/27/2026, and 17935 shares on 04/28/2026. Cash proceeds are shown for each transaction, including 1543369.00 and 544319.00 on the larger April trades.

How many MapLight (MPLT) shares are currently outstanding according to this notice?

The notice reports 42618165 shares of MapLight voting common stock outstanding. This figure provides context for the planned sale of 36979 shares; it is a baseline outstanding share count, not the number being sold under the Form 144 notice.

What type of transaction generated the MPLT shares to be sold?

The shares covered by the Form 144 notice are tied to a restricted stock unit settlement dated 07/15/2026 involving MapLight Therapeutics, Inc. This indicates the securities to be sold arose from equity compensation rather than an open-market purchase or separate acquisition.

Which broker is listed for the planned MapLight (MPLT) share sale?

The planned sale of 36979 shares of MapLight voting common stock is listed as being handled by Morgan Stanley Smith Barney LLC, located at 1 New York Plaza, 8th Floor, New York, NY 10004, with the shares expected to trade on Nasdaq around 07/15/2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/15/2026 - 07:59 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001709954
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	MapLight Therapeutics, Inc.
SEC File Number	001-42914
Address of Issuer	800 Chesapeake Drive Redwood City CALIFORNIA 94063
Phone	(617)-984-6300
Name of Person for Whose Account the Securities are To Be Sold	Jonathan Gillis
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
MapLight voting common stock	Morgan Stanley Smith Barney LLC 1 New York Plaza 8th Floor New York NY 10004	36979	1401874.00	42618165	07/15/2026	Nasdaq

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
MapLight voting common stock	07/15/2026	Restricted stock unit settlement	MapLight Therapeutics, Inc.			36979	07/15/2026	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Jonathan Gillis 800 Chesapeake Drive Redwood City CA 94063	MapLight voting common stock	04/15/2026	3590	95530.00
Jonathan Gillis 800 Chesapeake Drive Redwood City CA 94063	MapLight voting common stock	04/27/2026	51900	1543369.00
Jonathan Gillis 800 Chesapeake Drive Redwood City CA 94063	MapLight voting common stock	04/28/2026	17935	544319.00

144: Remarks and Signature

Remarks	Shares to be sold solely to satisfy tax-withholding obligations in connection with restricted stock unit vesting.
Date of Notice	07/15/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Jonathan Gillis
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)